Table 3.
MSC based therapy clinical trials for COVID-19.
| NCT No. | Title | Status | Company Name | Disease/Conditions | Route of Administration | Intervention/Mechanism Target | Results | Phase |
|---|---|---|---|---|---|---|---|---|
| NCT04333368 | Cell therapy using Umbilical cord-derived Mesenchymal Stromal Cells in SARS-CoV-2 related ARDS (STROMA-CoV2) | Recruiting | Hopitaux de Paris | COVID-19 | Intravenous | Participants will receive 1 × 106 UC-MSCs in 60 min. Via peripheral or central venous line | N/A | 1 and 2 |
| NCT04392778 | Clinical use of stem cells for the treatment of COVID-19 | Recruiting | SBÜ | COVID-19, Pneumonia, Multiple Organ Failure, CoronaVirus Infection | Intravenous | Participants will receive 3 × 106 MSC on Day 0, 3 and 6. | N/A | 1 and 2 |
| NCT04252118 | Mesenchymal stem cell treatment for pneumonia patients infected with COVID-19 | Recruiting | Beijing 302 Hospital | COVID-19 | Intravenous | Participants will receive 3 × 107 of MSCs on day 0, 3 and 6 | N/A | 1 |
| NCT04348435 | A randomized, double-blind, placebo-controlled clinical trial to determine the safety and efficacy of hope biosciences allogenic mesenchymal stem cell therapy (HB-adMSCs) to provide protection against COVID-19 | Enrolling by Invitation | Hope biosciences | COVID-19 | Intravenous | 2 × 108, 1 × 108 0.5 × 108 and 0.1 × 108 Allogenic HB-adMSCs given to 4 different sets participants on day 0, 2, 6, 10, and day 14 | N/A | 2 |
| NCT04366063 | Mesenchymal Stem cell Therapy for SARS-CoV-2 related Acute Respiratory Distress Syndrome | Recruiting | Royan Institute | COVID-19 | Intravenous | Participants will receive 2 doses of 100 × 106 MSC at day 0 and 2 and 2 doses of EVs at day 4 and 6 | N/A | 2 and 3 |
| NCT04288102 | Treatment with mesenchymal system cells for severe Coronavirus Disease 2019 (COVID-19) | Recruiting | Beijing 302 | COVID-19 | Intravenous | Participants will receive 4 × 107 MSCs 3 times a day on day 0, 3 and 6 | N/A | 2 |
| NCT04349631 | A Clinical Trial to Determine the safety and efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to provide protection Against COVID-19 | Enrolling by Invitation | Hope biosciences | COVID-19 | Intravenous | Participants will receive 5 IV infusions of autologous, AD-MSCs collected and infused and follow up on week 6, 14, 26 | N/A | 2 |
| NCT04324996 | A Phase I/II Study of universal off-the-shelf- NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 | Recruiting | Chongqing Public Health Medical Center | COVID-19 | Intravenous | Participants will receive 1 × 108 cells administered per kilogram of body weight | N/A | 1 and 2 |
| NCT04273646 | Study of Human Umbilical Cord Mesenchymal Stem cells in the treatment of Severe COVID-19 | Not recruiting yet | Wuhan Union Hospital China | COVID-19, 2019 Novel Coronavirus pneumonia | Intravenous | Participants will receive 0.5 × 106 UC-MSCs cells/kg body weight administered on day 1, day 3, day 5, and day 7 | N/A | N/A |
| NCT04397471 | A study to collect bone marrow for process development and production of BM-MSC to treat severe COVID-19 Pneumonitis (COMET20d | Not recruiting yet | Cambridge Cellular Therapies Laboratory | COVID-19, Pneumonia | Donation | 30–80 mL sample of bone marrow collected from posterior superior iliac crests | N/A | N/A |
| NCT04382547 | Treatment of COVID-19 Associated Pneumonia with Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells | Enrolling by Invitation | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | COVID-19, Pneumonia | Intravenous | Participants will receive standard treatments and also allogenic pooled olfactory mucosa derived MSCs | N/A | 1 and 2 |
| NCT04366271 | Clinical Trial of Allogenic Mesenchymal Cells from Umbilical Cord Tissue with Patients with COVID-19 (MESCEL-COVID-19) | Recruiting | Hospital Infantil Universitario Nino Jesus, Madrid Spain | COVID-19 | Intravenous | Participants will receive 1 infusion of undifferentiated allogenic UC-MSCs | N/A | 2 |
| NCT04361942 | Treatment of Severe COVID-19 Pneumonia with Allogeneic Mesenchymal Stromal Cells (COVID_MSV) (COVID_MSV) | Recruiting | Red de Terapia Celular | COVID-19, Pneumonia | Intravenous | Participants will receive 1 × 106 MSCs | N/A | 2 |
| NCT04346368 | Bone Marrow-Derived Mesenchymal Stem cell treatment for severe patients with coronavirus disease 2019 (COVID-19 | Not recruiting yet | Guangzhou Institute of Respiratory Disease | COVID-19 | Intravenous | Participants will receive 1 × 106 MSCs kg/body weight on day 1 | N/A | 1 and 2 |
| NCT04416139 | Mesenchymal stem cells for acute respiratory distress Syndrome due to COVID-19 | Recruiting | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | COVID-19 | Intravenous | Participants will receive a single dose of 1 × 106 MSCs | N/A | 2 |
| NCT04336254 | Safety and Efficacy Study of Allogenic Human Dental Pulp Mesenchymal Stem Cells to treat severe COVID-19 Patients | Recruiting | Renmin Hospital of Wuhan University | COVID-19 | Intravenous | Participants will receive 3 × 107 human dental pulp stem cells on day 1, day 4 and day 7 | N/A | 1 and 2 |
| NCT04428801 | Autologous Adipose-derived Stem cells (Ad-MSCs) for COVID-19 | Not recruiting yet | Celltex Therapeutics Corporation | COVID-19 | Intravenous | Participants will receive 2 × 108 Ad-MSCs on day 0, day 3 and day 6 | N/A | 2 |
| NCT04269525 | Umbilical Cord (UC)-Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) Pneumonia | Recruiting | ZhiYong Peng, Zhongnan Hospital | COVID-19 Pneumonia | Intravenous | Participants will receive UC-MSC infusions and day 1, day 3 and day 5 | N/A | 2 |
| NCT04429763 | Safety and Efficacy of Mesenchymal Stem Cells in the management of severe COVID-19 pneumonia | Not recruiting yet | Trustem | COVID-19 | Intravenous | Participants will receive 1 dose of 1 × 106 MSCs | N/A | 2 |
| NCT04366323 | Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients with Severe Pneumonia Due to COVID-19 | Recruiting | Andalusian Network for design and translation of Advanced Therapies | COVID-19 | Intravenous | Participants will receive 8 × 107 allogenic Ad-MSCs | N/A | 1 and 2 |
| NCT04352803 | Adipose Mesenchymal cells for Abadement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease | Not recruiting yet | Regeneris Medical | COVID-19, Cytokine Storm | Intravenous | Participants will receive 0.5 × 106 autologous ad-MSCs | N/A | 1 and 2 |
| NCT04398303 | ACT-20 in Patients with severe COVID-19 Pneumonia | Not recruiting yet | Aspire Health Science | COVID-19 Pneumonia | Intravenous | Participants will receive 1 × 106 allogenic human umbilical derived MSCs | N/A | 2 |
| NCT04339660 | Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia | Recruiting | Puren Hospital Affliated to Wuhan University of Science and Technology | COVID-19 | Intravenous | Participants will receive 1 × 106 per kg/bodyweight UC-MSCs | N/A | 1 |
| NCT04444271 | Mesenchymal Stem Cell Infusion for COVID-19 Infection | Recruiting | Armed Forces Bone Marrow | COVID-19 | Intravenous | Participants will receive 1 × 106 cells/kg body weight of MSCs | N/A | 1 and 2 |
| 2020-001682-36 | Double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV®-allo) in acute respiratory failure in patients with COVID-19 pneumonia. | Ongoing | CITOSPIN S.L. | COVID-19 | Intravenous | Adult allogeneic stem cell mesenchymal stem cells expanded in suspension | N/A | 1 |
| NCT0444520 | A Study of Cell Therapy in COVID-19 Subjects with Acute Kidney Injury Who Are Receiving Renal Replacement Therapy | Not recruiting yet | Sentien Biotechnologies, Inc. | COVID-19 | Integration | Allogenic SB-101 biologic combination device | N/A | 1 |
| NCT04461925 | Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs | Recruiting | Institute of Cell Therapy | COVID-19 and Pneumonia | Intravenous | Participants will receive 1 × 106 cells/kg body weight 3 times a day on day 1, 4 and 7 | N/A | 1 and 2 |
| NCT04445454 | Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection | Recruiting | University of Liege | COVID-19 | Intravenous | Participants will receive 3 doses of (1.5)–3.0 × 106/BM-MSC kg/body weight at 3–4 days interval | N/A | 1 and 2 |
| NCT04437823 | Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients | Recruiting | Jinnah Hospital | COVID-19 | Intravenous | Participants will receive 5 × 105 of UC-MSCs on day 1,3 and 5 | N/A | 2 |
| NCT04456361 | Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 | Active, not recruiting | Instituto de Medicina Regenerativa | COVID-19 | Intravenous | Participants will receive 1 × 108 of Wharton jelly derived UC-MSCs | N/A | 2 |
| NCT04457609 | Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically Ill COVID-19 Patients | Recruiting | Indonesia University | COVID-19 | Intravenous | Participants will 1st receive standardized treatment oseltamivir and azithromycin and then 1 × 106 UC-MSCs in 100 cc of 0.9% NaCl in 1 h | N/A | 2 and 3 |
| NCT04467047 | Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19 (COVID19) | Not recruiting yet | Hospital de Clinicas de Porto Alegre | COVID-19 | Intravenous | Participants will receive 1 × 106 MSCs | N/A | 1 |
| NCT04466098 | Multiple Dosing of Mesenchymal Stromal Cells in Patients with ARDS (COVID-19) | Not recruiting yet | Masonic Cancer Center, University of Minnesota | COVID-19 | Intravenous | Participants will receive a thawed product consisting of 300 × 106 in DMSO in 1: w/ Dextran 40 + 5% human serum albumin | N/A | 2 |
| NCT04486001 | Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19 (CoronaStem1) | Not recruiting yet | Personalized Stem Cells, Inc. | COVD-19 | Intravenous | Participants will receive adipose derived stem cells | N/A | 1 |
| NCT04490486 | Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 (COVID-19) | Not recruiting yet | Joshua M Hare | COVID-19 | Intravenous | Participants will receive 1 × 108 UC-MSCS on day 0 and day 3 | N/A | 1 |
| NCT04456439 | Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease (COVID-19) | Available | Mesoblast International Sàrl | COVID-19 | Intravenous | Participants will receive 2 × 106 remestemcel-L within a 5-day period | N/A | N/A |
| NCT04313322 | Treatment of COVID-19 Patients using Wharton Jelly Mesenchymal Stem Cells | Recruiting | Stem Cells Arabia | COVID-19 | Intravenous | Participants will receive WJ-MSCs suspended in 25 mL of saline solution | N/A | 1 |
| NCT04371601 | Safety and effectiveness of mesenchymal stem cells in the treatment of pneumonia of coronavirus disease 2019 | Active, Not recruiting | Fuzhou General Hospital | COVID-19 Pneumonia | Intravenous | Participants will first receive standard treatment (oseltamivir and hormones) followed by 1 dose of 1 × 106 cells kg/body weight once daily for 4 days | N/A | 1 |
| NCT04362189 | Efficacy and Safety of Allogenic HB-adMSCs for the treatment of COVID-19 | Recruiting | Hope biosciences | COVID-19 | Intravenous | Participants will receive 1 × 108 of HB-adMSCs on day 0, 3, 7 and 10 | N/A | 2 |
| NCT04384445 | Organicell Flow for Patients With COVID-19 | Not yet recruiting | Organicell Regenerative Medicine | COVID-19 | Intravenous | Participants will receive 1 mL of organicell flow on days 0, 4, and 8 | N/a | 1 and 2 |
| NCT04341610 | ASC Therapy for Patients with Severe Respiratory COVID-19 (ASC COVID-19) | Withdrawn (Not approved by ethical committee) | Rigshospitalet, Denmark | Respiratory tract diseases (COVID-19) | Intravenous | 100 million allogenic adipose-derived mesenchymal stem cells in 100 mL saline | N/A | 1 and 2 |
| NCT04293692 | Therapy for Pneumonia Patients Infected by 2019 Novel Coronavirus | Withdrawn (Patients were transferred to designated hospitals for treatment as needed, the clinical trials cannot be conducted.) | Puren Hospital Affiliated to Wuhan University of Science and Technology | COVID | Intravenous | 0.5 × 106 UC-MSCs kg/body weight suspended in 100 mL saline on day 1, day 3, day 5 and day 7 | N/A | N/A |
N/A= Not yet available.